A study to evaluate the Bio-enhancing activity of Siddha drug Thirikaduku Chooranam along with Anti- Tuberculosis drugs among the Pulmonary Tuberculosis patients.
Not Applicable
- Conditions
- Health Condition 1: J988- Other specified respiratory disorders
- Registration Number
- CTRI/2021/02/031206
- Lead Sponsor
- The Director General
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients under DOTS ( Anti- Tuberculosis) Therapy
Category 1 for new smear positive patients with pulmonary TB.
Exclusion Criteria
h/o Throat cancer
h/o Influenza
h/o Pneumonia
h/o Bronchitis
h/o COPD
h/o Patients under treatment for any disease other than PT.
Pregnant and Lactating mothers
h/o HIV positive and AIDS.
Other than Category 1 pulmonary TB.
If the participant developed with any ADR after taking the standard or Trial drug.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessing the Bio-enhancing activity of the trial drug by HPLC method in the First line Anti- Tuberculosis drugs among the Category-1 Pulmonary Tuberculosis patients.Timepoint: 35 days
- Secondary Outcome Measures
Name Time Method Assessing the bio- availability of the First line Anti- Tuberculosis drugs on integration with Thirikaduku chooranam among the Category-1 Pulmonary Tuberculosis patients through HPLC method.Timepoint: 35 days